Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 7/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 4/20 | 0.33 |
| ▸ | PPARD | Q03181 | 3/20 | 0.33 |
| ▸ | PLAT | P00750 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1613466 | 0.84 | AR (0.40) | PDE2API4KBPLATMAPTNPC1 | |
| SCHEMBL15926352 | 0.84 | MAPT (0.36) | PDE2AKMT2ATP53MAPTLMNA | |
| SCHEMBL1614735 | 0.79 | PLAT (0.33) | PDE2AKMT2APLATMAPTNPC1 | |
| SCHEMBL1614928 | 0.79 | KCNQ3 (0.36) | PDE2APLATLMNA | |
| SCHEMBL15926362 | 0.76 | AR (0.37) | PDE2APLAT | |
| SCHEMBL15926318 | 0.72 | MAPK14 (0.32) | MAPT | |
| SCHEMBL15926314 | 0.72 | KCNQ3 (0.36) | PDE2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL1614666 | 0.71 | MAPT (0.33) | MAPT | |
| SCHEMBL15926328 | 0.70 | MAPK14 (0.31) | MAPT | |
| SCHEMBL1615018 | 0.68 | HCAR2 (0.35) | PDE2AKMT2APLATMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796285-B2 | Pyrazolo [1,5-a]-pyrimidones derivatives and pharmaceutical compositions and uses thereof | HEBEI MEDICAL UNIVERSITY (CN) | 2014-08-05 | — | — | US | disclosed |
| US-20120088775-A1 | Pyrazolo-[1,5-a]-Pyrimidones Derivatives and Pharmaceutical Compositions and Uses Thereof | PEKING UNIVERSITY (CN) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088775-A1 | Pyrazolo-[1,5-a]-Pyrimidones Derivatives and Pharmaceutical Compositions and Uses Thereof | KCNJ2, KCNQ5, KCNJ11 | PDE2A 706/4885PDE5A 394/4885PI4KB 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.